1
Cristina Alonso Alija, Erwin Bischoff, Klaus Münter, Johannes Peter Stasch, Elke Stahl, Stefan Weigand, Achim Feurer: Carbamate-substituted pyrazolopyridines. Bayer HealthCare, February 6, 2007: US07173037 (66 worldwide citation)

The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.


2
Klaus Münter, Michael Kirchengast: Method for combating obesity. Knoll Aktiengesellschaft, Keil & Weinkauf, March 6, 2001: US06197780 (13 worldwide citation)

Diseases caused by obesity are treated with endothelin receptor antagonists. Diseases treated include those frequently associated with obesity such as hypertension, type 2 diabetes, hyperlipidemia, chronic kidney failure, arteriosclerosis and gout.


3
Klaus Münter, Michael Kirchengast, Horst Korioth: Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation. Abbott Laboratories, Keil & Weinkauf, December 11, 2001: US06329384 (12 worldwide citation)

A combination of endothelin antagonists and RAS inhibitor is described. The combination is suitable for controlling diseases.


4
Michael Kirchengast, Klaus Münter: Endothelin antagonist and beta receptor blocking agent as combined preparations. Abbott Laboratories, Keil & Weinkauf, March 5, 2002: US06352992 (12 worldwide citation)

A combination of endothelin antagonists and beta-receptor blockers is described. The combination is suitable for controlling diseases.


5
Achim Feurer, Samir Bennabi, Heike Heckroth, Hartmut Schirok, Joachim Mittendorf, Raimund Kast, Johannes Peter Stasch, Jean Mark Gnoth, Klaus Münter, Dieter Lang, Santiago Figueroa Perez, Heimo Ehmke: Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors. Bayer Schering Pharma Aktiengesellschaft, Edwards Angell Palmer & Dodge, Nicholas J DiCeglie Jr, Barry Kramer, June 15, 2010: US07737153 (7 worldwide citation)

The invention relates to heteroaryloxy-substituted phenylaminopyrimidines, to methods for the production thereof, and to the use of the same for producing medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular diseases. The inventive compounds inhibit Rho-Kinase.


6
Stefan Weigand, Erwin Bischoff, Klaus Münter, Johannes Peter Stasch, Elke Stahl: Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators. Bayer Healthcare, November 14, 2006: US07135474 (6 worldwide citation)

This application relates to compounds of the formula (I) in which R1 is chlorine, cyano, trifluoromethyl or methoxy and R2 is hydrogen or flurorine; or R1 and R2 are both fluorine; and to pharmaceutically acceptable salts of these materials. Pharmaceutical compositions containing these materials, an ...


7
Stephan Bartel, Michael Hahn, Wahed Ahmed Moradi, Klaus Münter, Thomas Rölle, Johannes Peter Stasch, Karl Heinz Schlemmer, Frank Wunder: Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders. Bayer Schering Pharma Aktiengellschaft, Karen B King, August 16, 2011: US07998988 (5 worldwide citation)

The invention relates to biphenyl compounds of formula (I): wherein U, V and W together form a group of the formula *—CH═CH—CH<, *—CH2—CH2—CH< or *—CH2—CH2—N<, in which * means the point of linkage to the phenyl ring; A is O or CH2; and D, E, X, Y, Z, R1, R2, o, n, and p are as defined in the specif ...


8
Santiago Figueroa Perez, Peter Kolkhof, Lars Bärfacker, Ingo Flamme, Karl Heinz Schlemmer, Alexander Kuhl, Rolf Grosser, Klaus Münter, Andreas Knorr: Aryl-or heteroaryl-substituted pyrido[2,3-d] pyrimidines and pharmaceutical compositions of the same. Bayer Intellectual Property, Karen B King, March 19, 2013: US08399471 (3 worldwide citation)

The present application relates to novel aryl- or heteroaryl-substitued pyrido[2,3-d] pyrimidines of formula (I), pharmaceuitical compositions of the same, and a process for their preparation. Formula(I) is: wherein Ar is an aryl or heteroaryl substituent, and R1, R2, R3, Ar, D, and E are as defined ...


9
Lars Bärfacker, Peter Kolkhof, Karl Heinz Schlemmer, Rolf Grosser, Adam Nitsche, Martina Klein, Klaus Münter, Barbara Albrecht Küpper, Elke Hartmann: Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof. Bayer Intellectual Property, Karen B King, May 7, 2013: US08436180 (1 worldwide citation)

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, es ...


10
Hartmut Schirok, Johannes Peter Stasch, Raimund Kast, Klaus Münter, Marc Jean Gnoth, Santiago Figureoa Perez, Michael Thutewohl, Samir Bennabi, Dieter Lang, Joachim Mittendorf, Martin Radtke, Heimo Ehmke: Substituted phenylamino-pyrimidines. Bayer Schering Pharma Aktiengesellschaft, Thomas C Blankinship, May 25, 2010: US07723347 (1 worldwide citation)

The invention relates to substituted phenylaminopyrimidines, to a process for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular cardiovascular disorders.